Literature DB >> 29099547

Treating Pediatric Anxiety: Initial Use of SSRIs and Other Antianxiety Prescription Medications.

Greta A Bushnell1,2,3, Scott N Compton4, Stacie B Dusetzina5, Bradley N Gaynes6, M Alan Brookhart2, John T Walkup7,8, Moira A Rynn9,10, Til Stürmer2.   

Abstract

OBJECTIVE: Multiple pharmacotherapies for treating anxiety disorders exist, including selective serotonin reuptake inhibitors (SSRIs), the recommended first-line pharmacotherapy for pediatric anxiety. We sought to describe initial antianxiety medication use in children and estimate how long antianxiety medications were continued.
METHODS: In a large commercial claims database, we identified children (3-17 years) initiating prescription antianxiety medication from 2004 to 2014 with a recent anxiety diagnosis (ICD-9-CM = 293.84, 300.0x, 300.2x, 300.3x, 309.21, 309.81, 313.23). We estimated the proportion of children initiating each medication class across the study period and used multivariable regression to evaluate factors associated with initiation with an SSRI. We evaluated treatment length for each initial medication class.
RESULTS: Of 84,500 children initiating antianxiety medication, 70% initiated with an SSRI (63% [95% CI, 62%-63%] SSRI alone, 7% [95% CI, 7%-7%] SSRI + another antianxiety medication). Non-SSRI medications initiated included benzodiazepines (8%), non-SSRI antidepressants (7%), hydroxyzine (4%), and atypical antipsychotics (3%). Anxiety disorder, age, provider type, and comorbid diagnoses were associated with initial medication class. The proportion of children refilling their initial medication ranged from 19% (95% CI, 18%-20%) of hydroxyzine initiators and 25% (95% CI, 24%-26%) of benzodiazepine initiators to 81% (95% CI, 80%-81%) of SSRI initiators. Over half (55%, 95% CI, 55%-56%) of SSRI initiators continued SSRI treatment for 6 months.
CONCLUSIONS: SSRIs are the most commonly used first-line medication for pediatric anxiety disorders, with about half of SSRI initiators continuing treatment for 6 months. Still, a third began therapy on a non-SSRI medication, for which there is limited evidence of effectiveness for pediatric anxiety, and a notable proportion of children initiated with 2 antianxiety medication classes. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29099547      PMCID: PMC6468981          DOI: 10.4088/JCP.16m11415

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  42 in total

1.  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

Authors:  Mark Olfson; Carlos Blanco; Linxu Liu; Carmen Moreno; Gonzalo Laje
Journal:  Arch Gen Psychiatry       Date:  2006-06

2.  Parental preferences for FDA-approved medications prescribed for their children.

Authors:  Esther Y Yoon; Sarah J Clark; Amy Butchart; Dianne Singer; Matthew M Davis
Journal:  Clin Pediatr (Phila)       Date:  2010-11-22       Impact factor: 1.168

3.  Early adolescent symptoms of social phobia prospectively predict alcohol use.

Authors:  Jennifer Dahne; Anne N Banducci; Gretchen Kurdziel; Laura MacPherson
Journal:  J Stud Alcohol Drugs       Date:  2014-11       Impact factor: 2.582

Review 4.  Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.

Authors:  Martin A Katzman
Journal:  J Affect Disord       Date:  2011-01       Impact factor: 4.839

5.  The Length of Child Anxiety Treatment in a Regional Health System.

Authors:  Stephen P H Whiteside; Chelsea M Ale; Brennan Young; Mark W Olsen; Bridget K Biggs; Melissa S Gregg; Jennifer R Geske; Kendra Homan
Journal:  Child Psychiatry Hum Dev       Date:  2016-12

6.  Trends in subthreshold psychiatric diagnoses for youth in community treatment.

Authors:  Daniel J Safer; Thiyagu Rajakannan; Mehmet Burcu; Julie M Zito
Journal:  JAMA Psychiatry       Date:  2015-01       Impact factor: 21.596

7.  Child anxiety in primary care: prevalent but untreated.

Authors:  Denise A Chavira; Murray B Stein; Kelly Bailey; Martin T Stein
Journal:  Depress Anxiety       Date:  2004       Impact factor: 6.505

Review 8.  Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder.

Authors: 
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-01       Impact factor: 8.829

9.  Practice parameter on the use of psychotropic medication in children and adolescents.

Authors:  John Walkup
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-09       Impact factor: 8.829

Review 10.  Assessment and management of anxiety disorders in children and adolescents.

Authors:  Cathy Creswell; Polly Waite; Peter J Cooper
Journal:  Arch Dis Child       Date:  2014-03-17       Impact factor: 3.791

View more
  9 in total

1.  Psychotherapy Claims Surrounding Pharmacotherapy Initiation in Children and Adolescents with Anxiety Disorders.

Authors:  Greta A Bushnell; Stacie B Dusetzina; Scott N Compton; Bradley N Gaynes; M Alan Brookhart; Til Stürmer
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-12-19       Impact factor: 2.576

2.  Benzodiazepine Treatment and Fracture Risk in Young Persons With Anxiety Disorders.

Authors:  Greta A Bushnell; Tobias Gerhard; Stephen Crystal; Mark Olfson
Journal:  Pediatrics       Date:  2020-06-04       Impact factor: 7.124

3.  Denying renal transplantation to an adolescent medical cannabis user: An ethical case study.

Authors:  Jennie E Ryan; Maia Noeder; Christine Burke; Samuel C Stubblefield; Salwa Sulieman; Elissa G Miller
Journal:  Pediatr Transplant       Date:  2019-05-23

4.  Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis.

Authors:  Jeffrey A Mills; Jeffrey R Strawn
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-11-01       Impact factor: 8.829

5.  Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders.

Authors:  Greta A Bushnell; M Alan Brookhart; Bradley N Gaynes; Scott N Compton; Stacie B Dusetzina; Til Stürmer
Journal:  Med Care       Date:  2018-06       Impact factor: 2.983

6.  Incidence of mental health hospitalizations, treated self-harm, and emergency room visits following new anxiety disorder diagnoses in privately insured U.S. children.

Authors:  Greta A Bushnell; Bradley N Gaynes; Scott N Compton; Stacie B Dusetzina; M Alan Brookhart; Til Stürmer
Journal:  Depress Anxiety       Date:  2018-10-24       Impact factor: 6.505

7.  Prescription Benzodiazepine Use in Privately Insured U.S. Children and Adolescents.

Authors:  Greta A Bushnell; Stephen Crystal; Mark Olfson
Journal:  Am J Prev Med       Date:  2019-12       Impact factor: 5.043

8.  Antidepressant Use in a 3- to 12-Year Follow-up of Anxious Youth: Results from the CAMELS Trial.

Authors:  Elana R Kagan; Hannah E Frank; Lesley A Norris; Sophie A Palitz; Erika A Chiappini; Mark J Knepley; Margaret E Crane; Katherine E Phillips; Golda S Ginsburg; Courtney Keeton; Anne Marie Albano; John Piacentini; Tara Peris; Scott Compton; Dara Sakolsky; Boris Birmaher; Philip C Kendall
Journal:  Child Psychiatry Hum Dev       Date:  2021-02

Review 9.  Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years?

Authors:  Jeffrey R Strawn; Lu Lu; Tara S Peris; Amir Levine; John T Walkup
Journal:  J Child Psychol Psychiatry       Date:  2020-06-05       Impact factor: 8.265

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.